Bioengineered microbes in disease therapy

Trends in Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 417-425

  Paton, Adrienne W ^a   Morona, Renato ^a   Paton, James C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GENE THERAPY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STAT3 PROTEIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIBIOTIC RESISTANCE; BIOENGINEERING; CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; CROHN DISEASE; DOSE RESPONSE; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC MANIPULATION; HUMAN; INFLAMMATORY DISEASE; LABORATORY; LACTOCOCCUS LACTIS; MICROORGANISM; MORBIDITY; MORTALITY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; QUORUM SENSING; RECOMBINANT DNA TECHNOLOGY; REVIEW; RNA INTERFERENCE; SALMONELLA; STREPTOCOCCUS GORDONII; STREPTOCOCCUS PYOGENES; T CELL LYMPHOMA; UNSPECIFIED SIDE EFFECT;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BIOMEDICAL ENGINEERING; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; NEOPLASMS; PROBIOTICS;

BACTERIA (MICROORGANISMS);

EID: 84863100717     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.05.006     Document Type: Review

References (70)

1. Barbé S., et al. The use of clostridial spores for cancer treatment. J. Appl. Microbiol. 2006, 101:571-578.
2. Coley W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 1910, 3:1-48.
3. Morales A., et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 1976, 116:180-183.
4. Shintani Y., et al. Intravesical instillation therapy with Bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of Bacillus Calmette-Guérin immunotherapy. Int. J. Urol. 2007, 14:140-146.
5. Wei M.Q., et al. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett. 2008, 259:16-27.
6. Culligan E.P., et al. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009, 1:19.
7. Braat H., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4:754-759.
8. Huibregtse I.L., et al. Genetically modified Lactococcus lactis for delivery of human interleukin-10 to dendritic cells. Gastroenterol. Res. Pract. 2012, 2012:639291.
9. Vandenbroucke K., et al. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010, 3:49-56.
10. Caluwaerts S., et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010, 46:564-570.
11. Ricci S., et al. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 2003, 3:15.
12. Porzio S., et al. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. BMC Biotechnol. 2004, 4:27.
13. Palffy R., et al. Salmonella-mediated gene therapy in experimental colitis in mice. Exp. Biol. Med. (Maywood) 2011, 236:177-183.
14. Heppner F., Möse J.R. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir. (Wien) 1978, 42:123-125.
15. Liu S.C., et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002, 9:291-296.
16. Barbé S., et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol. Lett. 2005, 246:67-73.
17. Stritzker J., et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int. J. Med. Microbiol. 2007, 297:151-162.
18. Stritzker J., et al. Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. Bioeng. Bugs 2010, 1:139-145.
19. Anderson J.C., et al. Environmentally controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 2006, 355:619-627.
20. Zhang X.L., et al. Salmonella typhi: from a human pathogen to a vaccine vector. Cell. Mol. Immunol. 2008, 5:91-97.
21. Galen J.E., et al. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol. Cell Biol. 2009, 87:400-412.
22. Forbes N.S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 2010, 10:785-794.
23. Ganai S., et al. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther. 2011, 18:457-466.
24. Zhao M., et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:755-760.
25. Zhao M., et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10170-10174.
26. Zhao M., et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006, 66:7647-7652.
27. Hayashi K., et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J. Cell. Biochem. 2009, 106:992-998.
28. Toso J.F., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 2002, 20:142-152.
29. Nemunaitis J., et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003, 10:737-744.
30. Ganai S., et al. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br. J. Cancer 2009, 101:1683-1691.
31. Loeffler M., et al. Inhibition of tumor growth using Salmonella expressing Fas ligand. J. Natl. Cancer Inst. 2008, 100:1113-1116.
32. al-Ramadi B.K., et al. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin. Immunol. 2009, 130:89-97.
33. Sorenson B.S., et al. Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. J. Pediatr. Surg. 2008, 43:1153-1158.
34. Loeffler M., et al. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther. 2008, 15:787-794.
35. Loeffler M., et al. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol. Immunother. 2009, 58:769-775.
36. Loeffler M., et al. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12879-12883.
37. Ryan R.M., et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 2009, 16:329-339.
38. Arrach N., et al. Salmonella promoters preferentially activated inside tumors. Cancer Res. 2008, 68:4827-4832.
39. Lee C.H., et al. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther. 2005, 12:175-184.
40. Fu W., et al. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors. Cancer Gene Ther. 2008, 15:474-484.
41. Fu W., et al. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models. J. Gene Med. 2008, 10:690-701.
42. Yoon W.S., et al. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 ligand expression plasmids in melanoma-bearing mouse. Biotechnol. Lett. 2007, 29:511-516.
43. Tangney M., Gahan C.G. Listeria monocytogenes as a vector for anti-cancer therapies. Curr. Gene Ther. 2010, 10:46-55.
44. Xiang S., et al. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat. Biotechnol. 2006, 24:697-702.
45. Guo H., et al. Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi. Gene Ther. 2011, 18:95-105.
46. Zhang L., et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar Typhimurium carrying plasmid-based small interfering RNAs. Cancer Res. 2007, 67:5859-5864.
47. Yang N., et al. Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol. Ther. 2008, 7:145-151.
48. Akin D., et al. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat. Nanotechnol. 2007, 2:441-449.
49. Shahabi V., et al. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng. Bugs 2010, 1:235-243.
50. Hemmerling A., et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex. Transm. Dis. 2010, 37:745-750.
51. Lagenaur L.A., et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 2011, 4:648-657.
52. Duan F., March J.C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11260-11264.
53. Paton A.W., et al. Designer probiotics for prevention of enteric infections. Nat. Rev. Microbiol. 2006, 4:193-200.
54. Buchholz U., et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N. Engl. J. Med. 2011, 365:1763-1770.
55. Paton A.W., et al. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 2000, 6:265-270.
56. Paton A.W., et al. Recombinant probiotics for treatment and prevention of travellers' diarrhea. Gastroenterology 2005, 128:1219-1228.
57. Focareta A., et al. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006, 130:1688-1695.
58. Kitov P.I., et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000, 403:669-672.
59. Ilg K., et al. Glycomimicry: display of the GM3 sugar epitope on Escherichia coli and Salmonella enterica sv Typhimurium. Glycobiology 2010, 20:1289-1297.
60. Yavuz E., et al. Glycomimicry: display of fucosylation on the lipo-oligosaccharide of recombinant Escherichia coli K12. Glycoconj. J. 2011, 28:39-47.
61. Paton J.C., et al. Oral administration of formalin-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga toxigenic Escherichia coli. Infect. Immun. 2001, 69:1389-1393.
62. Langemann T., et al. The Bacterial Ghost platform system: production and applications. Bioeng. Bugs 2010, 1:326-336.
63. MacDiarmid J.A., Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr. Opin. Biotechnol. 2011, 22:909-916.
64. MacDiarmid J.A., et al. Bacterially derived 400nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007, 11:431-445.
65. MacDiarmid J.A., et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 2009, 27:643-651.
66. Parkes G.C., et al. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect. Dis. 2009, 9:237-244.
67. Banerjee P., et al. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog. 2009, 1:8.
68. Tien M.T., et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J. Immunol. 2006, 176:1228-1237.
69. Ryan K.A., et al. Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Helicobacter pylori. J. Med. Microbiol. 2009, 58:996-1005.
70. Sundén F., et al. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 2010, 184:179-185.